Sobi closes out 24-year partnership with Pfizer; Belgian Exothera site gets thumbs up from FDA
As Sobi’s drug substance manufacturing contract for Pfizer’s antihemophilic drug ReFacto expires in Q1 of 2024, the company is making plans to
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
